CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas
Loélia Babin, Elissa Andraos, Steffen Fuchs, Chloé Bessière, Lola Colras, Sandra Dailhau, Cathy Quelen, Cindy Pinto, Iyad Daoudi, Romain Pfeifer, Ahmed Zamani, Marina Bousquet, Stéphane Pyronnet, Christine Gaspin, Laurence Lamant, Fabienne Meggetto
The paper identifies circZBTB46 as a driver of crizotinib resistance in ALK-positive lymphomas and shows its targeting restores drug sensitivity.
Leukemia · Jun 26, 2026Peer-reviewedCancer Biology